Call for Abstract
Scientific Program
5th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, will be organized around the theme “Exploring the Challenges in Pre & Post Formulations and Drug Delivery Systems”
Pharmaceutica 2015 is comprised of 11 tracks and 65 sessions designed to offer comprehensive sessions that address current issues in Pharmaceutica 2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Preformulation considerations for solid and semi solid dosage forms
- Track 1-2Preformulation considerations for solution and suspension formulations
- Track 1-3Preformulation considerations for freeze dried and parenteral formulations
- Track 1-4Preformulation considerations for inhalational dosage forms
- Track 1-5Stability studies and regulatory considerations
- Track 1-6Applications of analytical techniques in preformulation studies
- Track 2-1Advances in oral and nasal drug delivery
- Track 2-2Developments in ophthalmic drug delivery systems
- Track 2-3Topical drug delivery system
- Track 2-4Parenterals and implants in drug delivery
- Track 2-5Rectal and vaginal drug delivery
- Track 2-6Novel routes for insulin delivery
- Track 3-1Sustained, controlled, and modulated drug delivery
- Track 3-2Reservoir and osmotic drug delivery system
- Track 3-3Polymeric and transdermal drug delivery system
- Track 3-4Colloidal and vesicular drug delivery
- Track 3-5Medical devices and implants for effective drug delivery
- Track 3-6Biomaterial synthesis, characterization and engineering in focus with novel drug delivery
- Track 3-7Advances in manufacturing of devices for drug delivery
- Track 4-1Nanotechnology in advanced drug delivery
- Track 4-2Impact of nanoscience and nanotechnology on controlled drug delivery
- Track 4-3Nanomaterials in drug delivery systems
- Track 4-4Expectations for future micro and nanotechnologies
- Track 4-5Advances in nano drugs for cancer chemotherapy
- Track 4-6Multi component nano systems, quantam dots for effective drug delivery
- Track 4-7Recent advances in dendrimer based nanosystems
- Track 5-1Prodrugs and site-specific drug delivery
- Track 5-2Prodrugs in cancer chemotherapy
- Track 5-3Prodrug approach in CNS drug delivery
- Track 5-4Recent advances in prodrug approach
- Track 6-1CNS targeted drug delivery System
- Track 6-2Latest trends in targeted delivery for cancer treatment
- Track 6-3Cancer biomarkers: current issues and future directions
- Track 6-4In-vitro drug release characterization models
- Track 6-5Biomarkers in drug targeting and delivery system
- Track 6-6Novel delivery strategies in targeted drug delivery
- Track 6-7Significance of biomaterials in targeted drug delivery
- Track 7-1Problems involved and overcoming challenges in the delivery of poorly soluble drugs
- Track 7-2Novel approaches in the delivery of poorly soluble drugs
- Track 7-3Overcoming bioavailability hurdles for poorly soluble clinical candidates
- Track 7-4Rationale formulation design for poorly soluble compounds
- Track 7-5Overcoming challenges in protein drug delivery
- Track 7-6Challenges in pediatric and geriatric drug delivery
- Track 7-7Overcoming addictive nature of drugs.
- Track 8-1Anatomical, biochemical and physiological considerations in design and development of novel drug delivery systems
- Track 8-2Pharmacokinetics in drug design
- Track 8-3Pharmacokinetic behaviours of conventional and novel dosage forms
- Track 8-4In-silico drug discovery and development
- Track 8-5Computational methods in adme and toxicity studies
- Track 8-6Pharmacokinetic parameters for drug input and drug disposition
- Track 9-1Development of colloidal vaccine drug delivery systems
- Track 9-2Needle free vaccine drug delivery approach
- Track 9-3Importance of immunostimulatory adjuvant
- Track 9-4New generation vaccines for cancer therapy
- Track 9-5Novel trends in vaccine drug delivery
- Track 10-1Design and development of biotherapeutics
- Track 10-2Tools for biotherapeutics generation
- Track 10-3Dry biopharmaceuticals and applications
- Track 10-4Biopharmaceutical drugs from natural sources
- Track 10-5Formulation Techniques for Biopharmaceuticals
- Track 11-1Regulatory requirements
- Track 11-2Design controls
- Track 11-3Quality by Design (QbD)
- Track 11-4Regulatory audits CAPA and risk management
- Track 11-5Biocompatibility/Compliance testing